Related Experiment Video
Updated: Jun 8, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
The therapeutic implications of renin-angiotensin system blockade in diabetic retinopathy
1Department of Ophthalmology, University College Hospital, Galway, Ireland. vswetha@ausdoctors.net
Abstract:
Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycaemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Insights
Lowering high blood pressure is crucial for managing diabetic retinopathy. Inhibiting the renin-angiotensin-system (RAS) shows promise as a therapeutic strategy for diabetic eye disease.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- High blood pressure is a significant, modifiable risk factor for diabetic retinopathy.
- Diabetic retinopathy affects both type 1 and type 2 diabetes patients.
- The renin-angiotensin-system (RAS) is activated in diabetes, contributing to end-organ damage.
Purpose of the Study:
- To review therapeutic renin-angiotensin-system (RAS) inhibition for diabetic retinopathy.
- To emphasize recently published evidence on RAS inhibition in managing diabetic retinopathy.
Main Methods:
- Review of current scientific literature on RAS, hyperglycemia, and diabetic retinopathy.
- Analysis of pharmacological RAS inhibition strategies.
Main Results:
- Lowering blood pressure significantly reduces diabetic retinopathy development and progression.
- Hyperglycemia activates angiotensin AT1-receptor, leading to damage.
- Pharmacological RAS inhibition is a potentially beneficial therapeutic strategy.
Conclusions:
- RAS inhibition is a promising therapeutic approach for diabetic retinopathy.
- Further research is needed on RAS blockade as an adjunct therapy for diabetic retinopathy.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Diabetic Retinopathy
Diabetic Nephropathy
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

